Results 111 to 120 of about 331,356 (244)

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study. [PDF]

open access: yesKidney Int Rep, 2023
Rizk DV   +11 more
europepmc   +1 more source

Severe COVID-19 is associated with hyperactivation of the alternative complement pathway. [PDF]

open access: yesJ Allergy Clin Immunol, 2022
Boussier J   +16 more
europepmc   +1 more source

Therapeutic targeting of alternative pathway and C5 but not C5a protects from disease development in a preclinical model of autoimmune blistering dermatosis

open access: yesFrontiers in Immunology
IntroductionEpidermolysis Bullosa Acquisita (EBA) is an autoimmune blistering dermatosis characterized by autoantibodies (AAbs) against type VII collagen (COL7) located at the dermal epidermal junction (DEJ).
Björn Laffer   +7 more
doaj   +1 more source

Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial. [PDF]

open access: yesKidney Int Rep, 2022
Bomback AS   +7 more
europepmc   +1 more source

Complement Pathway Associated Glomerulopathies [PDF]

open access: yesEuropean Medical Journal, 2016
The complement system causes kidney injury in a variety of different diseases, and clinical evaluation of the complement system is an important part of the diagnostic workup of patients with glomerulonephritis.
Yasar Caliskan
doaj  

Home - About - Disclaimer - Privacy